enterovirus 71 vaccine + coxsackievirus A16 vaccine

**enterovirus 71 vaccine + coxsackievirus A16 vaccine** is a bivalent vaccine developed to provide broad protection against **hand, foot and mouth disease (HFMD)** caused principally by *enterovirus 71 (EV71)* and *coxsackievirus A16 (CA16)*[1][2][3][4][6]. Both inactivated and live-attenuated versions have been tested experimentally. - The vaccine combines inactivated or live-attenuated strains of EV71 and CA16 (as antigens), either as whole virus or virus-like particles (VLPs)[1][2][3][4]. - The **mechanism of action** is induction of virus-neutralizing antibodies against both EV71 and CA16, conferring balanced, dual protective immunity in animals and passive protection in neonatal mice[1][2][3][4]. - Some versions utilize recombinant or chimeric VLPs expressing neutralizing epitopes from both viruses[3][4]. - Primary indication: prevention of HFMD. - Developers include academic labs and vaccine science centers, notably institutes in China[1][4]. - No currently approved commercial product; all available evidence describes experimental or preclinical versions[1][2][3][4][5].

Other names

enterovirus 71 and coxsackievirus A16 bivalent vaccineenterovirus71 and coxsackievirus A16 bivalent vaccineenterovirus-71 and coxsackievirus A16 bivalent vaccineEV-A71/CV-A16 combination vaccinebivalent EV-A71/CV-A16 vaccine